DFINE, Inc. was an American medical device company with headquarters in San Jose, California.[4] It was known for its development of minimally invasive therapeutic devices built upon a radiofrequency platform for the treatment of spinal diseases.[5] The platform included two applications, the StabiliT Vertebral Augmentation System for the treatment of vertebral compression fractures[6] and the STAR Tumor Ablation System for pain relief treatment of metastatic spinal tumors.[7]

Number of locations
11 countries (direct in the U.S. and Germany)
Key people
Greg Barrett, CEO[2]
Dan Balbierz - Chief Development Officer[2]
ProductsStabiliT Vertebral Augmentation System[3]
STAR Tumor Ablation System
Number of employees


DFINE was founded in 2004 in San Jose, California.[1] It has had five rounds of funding since inception. The first being $35 million in 2009 led by Prospect Venture Partners.[8] In January 2010 it received an additional $2.8 million.[4] It received $36.2 million in equity finance in July 2010, led by Split Rock Partners with participation from OrbiMed, Prospect Venture Partners, and Vanguard Ventures.[9] Its fourth round was $25 million[10] with an additional $1.8 million coming in April 2012.

In 2011, DFINE was awarded a five-year Federal Supply Schedule from the United States Department of Veterans Affairs. The contract included DFINE supplying its StabiliT System and related products to the Veterans Health Administration.[citation needed]

Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, announced on June 06, 2016 that it has acquired DFINE, Inc. in a merger transaction through which DFINE became a wholly owned subsidiary of Merit. The purchase consideration was approximately $97.5 million in cash and was financed by a group of banks led by Wells Fargo and included Bank of America, HSBC and U.S. Bank.[11]


DFINE developed products for the treatment of spinal diseases using a radiofrequency platform.[1][12] The platform covers two procedures, one for the treatment of vertebral compression fractures and one for palliative treatment of metastatic spinal tumors. Both have received clearance from the United States Food and Drug Administration and CE Mark approval for use within the European Economic Area.[13]

StabiliT Vertebral Augmentation SystemEdit

The StabiliT System is an FDA cleared device that uses radiofrequency targeted vertebral augmentation (also written RF-TVA) to repair compression fractures in the vertebrae.[12] it is a minimally invasive procedure designed to preserve good bone while performing kyphoplasty.[6][12] In contrast with balloon kyphoplasty, RF-TVA is performed by a physician navigating within the vertebral body by placing a working canula into the vertebra and creating a cavity using a small chisel-like instrument.[12] The cavity is then filled with ultra-high viscosity bone cement which then permeates into the surrounding bone, stabilizing the fracture[3][6] and restoring vertebral height.[14] As of 2014, the system has been used to treat more than 15,000 spinal fractures worldwide.

STAR Tumor Ablation SystemEdit

The STAR Tumor Ablation System is an FDA-cleared medical device that uses targeted radiofrequency ablation (also written t-RFA) to heat and destroy cancerous tumors caused by metastatic disease that has spread to the spine, causing severe pain and discomfort.[15][16] STAR is not used as a treatment for cancer, but for pain relief. It is typically an outpatient procedure and can be performed using local anesthesia through a small incision. It works by placing a small steerable device into the vertebra which is guided by the physician to precisely target the tumor.[16] The system then ablates the tumor, destroying the tumor cells while minimizing damage to surrounding tissues. In some cases it has been shown to alleviate pain with one treatment.[16]

See alsoEdit


  1. ^ a b c Chandler, Michele (19 September 2010). "Silicon Valley startups bring innovations to back surgery". San Jose Business Journal. Retrieved 5 May 2014.
  2. ^ a b "DFINE Management Team". Dfine, Inc. Retrieved 5 May 2014.
  3. ^ a b Mauro, Matthew A. (2013). Image-Guided Interventions: Expert Radiology Series. Elsevier Health Sciences. ISBN 9781455753970.
  4. ^ a b Ricketts, Camille (11 January 2010). "DFine takes in $2.8M to heal spinal fractures". Venture Beat. Retrieved 5 May 2014.
  5. ^ Chandler, Michele (15 August 2010). "DFine Inc. cements future in vertebrae surgical market". San Jose Business Journal. Retrieved 5 May 2014.
  6. ^ a b c Krings, Timo (2011). Case-Based Interventional Neuroradiology. Thieme. ISBN 9781604063745.
  7. ^ Parikh, Ravi (22 August 2013). "DFINE STAR Tumor Ablation System Demonstrates Significant Clinical Benefit for Spinal Metastases". Med Gadget. Retrieved 5 May 2014.
  8. ^ "DFine Raises $35 Million". Private Equity Hub. 2 January 2009. Retrieved 5 May 2014.
  9. ^ Klein, Julie (15 July 2010). "DFine raises $36.2M to repair spine fractures". Venture Beat. Retrieved 5 May 2014.
  10. ^ "Dfine Closes $25M Equity Financing". Finsmes. 8 November 2011. Retrieved 5 May 2014.
  11. ^ Inc., Merit Medical Systems. "Merit Medical Acquires DFINE, Inc". GlobeNewswire News Room. Retrieved 2016-12-15. {{cite news}}: |last= has generic name (help)
  12. ^ a b c d Robertson, Scott C. (2011). Percutaneous Vertebral Augmentation: StabilitiT A New Delivery System for Vertebral Fractures. Advances in Minimally Invasive Surgery and Therapy for Spine and Nerves. Acta Neurochirurgica Supplementum. Vol. 108. pp. 191–195. doi:10.1007/978-3-211-99370-5_29. ISBN 978-3-211-99369-9. PMID 21107958.
  13. ^ Krishnamurthy, Gaurav (1 October 2013). "DFINE Gets CE Mark for STAR Tumor Ablation System". Med Gadget. Retrieved 5 May 2014.
  14. ^ Dalton, BE; AC Kohm; LE Miller; JE Block; RD Poser (2012). "Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty". Clin Interv Aging. 7: 525–31. doi:10.2147/CIA.S37025. PMC 3508556. PMID 23204845.
  15. ^ "DFine treatment OKd for spinal cancer". San Jose Business Journal. 4 October 2010. Retrieved 5 May 2014.
  16. ^ a b c Jennings, J.; W. Irving; B. Gregory; D. Coldwell; B. Zablow; C. DePena; A. Brook (April 2013). "Image-guided targeted radiofrequency ablation (t-RFA) of spinal tumors using a novel bipolar navigational device". Journal of Vascular and Interventional Radiology. 24 (4): S44–S45. doi:10.1016/j.jvir.2013.01.100. Retrieved 5 May 2014.

External linksEdit